Physiomics Director Ian Bagnall Increases Stake with £5,000 Share Purchase
核心洞察
Physiomics Director Ian Bagnall acquired 1,111,111 ordinary shares at 0.45p per share through market purchases on 14 July 2026.
The transaction brings Mr Bagnall's total holding to 16,111,111 ordinary shares, representing approximately 3.55% of the company's issued share capital.
Physiomics is a mathematical modelling and data science company supporting drug development, with clients including Merck KGaA, Astellas, and Bicycle Therapeutics.
Physiomics plc (搜索) (AIM: PYC), a mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, has disclosed that Director Ian Bagnall has increased his equity position in the company through a series of market purchases.
The transaction, announced on 14 July 2026, involved the acquisition of 1,111,111 new ordinary shares of 0.4p each at a price of 0.45p per ordinary share. Following the purchase, Mr Bagnall's total holding stands at 16,111,111 ordinary shares, representing approximately 3.55% of the company's issued share capital.
The notification was made in accordance with the requirements of the UK Market Abuse Regulation (UK MAR), with full details provided through the prescribed PDMR notification form.
Company Profile and Capabilities
Physiomics plc (搜索) combines expertise across modelling and simulation, biostatistics, data science, and bioinformatics, underpinned by deep biology knowledge, to assist biotechnology and pharmaceutical companies in streamlining their drug development programmes. The company's approach focuses on deriving insight from relevant and often disparate data to de-risk decision-making and optimise research design across discovery, preclinical, and clinical studies.
Central to Physiomics' offering is its proprietary Virtual Tumour technology, a computational platform that has been deployed across a substantial portfolio of commercial projects. To date, the Physiomics team has informed the development of over 140 commercial projects, with more than 125 targets and drugs modelled.
Client Base and Industry Reach
The company's client roster includes notable pharmaceutical and biotechnology organisations such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics (搜索), and Cancer Research UK (CRUK). This diverse client base underscores the broad applicability of Physiomics' modelling and simulation services across different therapeutic areas and stages of drug development.
The director share purchase signals continued confidence in the company's strategic direction as it supports the pharmaceutical industry's growing reliance on computational approaches to enhance the efficiency of therapeutic development.